MoonLake Immunotherapeutics Aligns with FDA on BLA Submission for Sonelokimab in HS, Reports Q1 Financials

summarizeSummary

MoonLake Immunotherapeutics announced a positive final pre-BLA meeting with the FDA for sonelokimab in HS, confirming the path to market, alongside reporting Q1 financials that show a strong cash runway.

check_boxKey Events

• FDA Alignment for BLA Submission

  The company and FDA aligned on submission plans and label strategy for sonelokimab in hidradenitis suppurativa (HS), including the acceptability of MIRA trial data and inclusion of VELA-TEEN adolescent data. This formalizes the positive outcome of the pre-BLA meeting held on April 1, 2026.

• Clear Path to Market

  No remaining gaps were identified in the pre-BLA process, with BLA submission planned for September 2026. The company intends to apply for Priority Review designation, with acceptance and review decision expected by end of November 2026.

• Strong Cash Position

  MoonLake ended Q1 2026 with $357.9 million in cash, cash equivalents, and short-term marketable debt securities, extending its cash runway to the end of 2027. Additionally, up to $400 million in non-dilutive funds remain available through its debt facility.

• Upcoming Milestones

  The company outlined several key clinical milestones for 2026, including 52-week data from VELA-1 and VELA-2 trials in HS (Q2 2026), and primary endpoint readouts for Phase 3 IZAR-1 (PsA) and VELA-TEEN (adolescent HS) trials (Mid 2026).

auto_awesomeAnalysis

This 8-K formally confirms the highly positive outcome of MoonLake's final pre-BLA meeting with the FDA for sonelokimab in hidradenitis suppurativa (HS), which was previously announced via press release on May 10, 2026. This regulatory alignment is a major de-risking event for the company's lead asset, paving a clear path for the BLA submission in September 2026. The accompanying Q1 financials, also reported in this filing, show a strong cash position extending the runway to late 2027, providing financial stability as the company progresses towards commercialization.